1 in 5 people in US with anxiety won’t seek treatment

Research from GeneSight® Mental Health Monitor reveals that 1 in 5 people in the US with anxiety won't seek treatment 

A survey by GeneSight® Mental Health Monitor,  a leader in genetic testing and precision medicine, has found that one in five people with mental health conditions in the US won't seek treatment until these symptoms take a toll on their lives.

Nearly half (46%) of all respondents rated their anxiety symptoms as moderate to severe over the past six months. 

Of those surveyed with a diagnosis of anxiety, 86% rated their symptoms as moderate to severe over the past six months. More than half of those diagnosed say they lived with symptoms for years or decades before seeking treatment. 

Other findings include: 

  • 36% of people who think they have anxiety are planning to seek treatment
  • 47% said a debilitating panic attack would cause them to get treatment
  •  Additional reasons included not being able to leave their homes (34%), sleep issues (31%), an unshakeable feeling of dread (30%) and a negative impact to relationships (30%)

“Imagine waiting until you lose your hearing to treat an ear infection. Patients who are experiencing anxiety symptoms shouldn’t wait to seek treatment,” said Robin Miller, Internist, MD, MHS, owner of Triune Integrative Medicine in Medford, Oregon.

“If you are afraid to go out, experiencing panic attacks, can’t sleep, or your relationships are suffering, you don’t have to live like this. You don't have to wait. You don't have to suffer for years. Help is out there – and treatment can help.” 

Share

Featured Articles

Healthcare Business roundup: Baxter, Sanofi & Eli Lilly

Baxter International to sell kidney care spin-off Vantive; Sanofi's consumer health unit ‘to be separated’; Eli Lilly to buy Morphic Holding for $3.2bn

Trane Technologies Helping US Hospitals Meet Climate Pledge

Christy Fetsch of Trane Technologies explains how the company is helping US hospitals meet White House sustainability pledges for US healthcare provision

Nestlé Health Science Targets Weight Loss Side-Effects

Nestlé Health Science launches nutrition initiative to counteract side effects of weight-loss drugs, including hollowed-out 'Ozempic Face'

Eli Lilly Alzheimer's Drug Kisunla Approved in US by FDA

Medical Devices & Pharma

WEF: Gender Health Gap 'Costs women 75mn years of Life'

Medical Devices & Pharma

Schneider: Swathe of NHS Failing to Measure Sustainability

Sustainability